Genetic determinants of drug resistance in mycobacterium tuberculosis and their diagnostic value

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 5, 2016, Pages 621-630

  Farhat, Maha R ^a,b   Sultana, Razvan ^c   Iartchouk, Oleg ^d   Bozeman, Sam ^e   Galagan, James ^f,g   Sisk, Peter ^h   Stolte, Christian ⁱ   Nebenzahl Guimaraes, Hanna ^j,k,l   Jacobson, Karen ^m,n   Sloutsky, Alexander ^b,o   Kaur, Devinder ^o   Posey, James ^p   Kreiswirth, Barry N ^q   Kurepina, Natalia ^q   Rigouts, Leen ^r,s   Streicher, Elizabeth M ⁿ   Victor, Tommie C ⁿ   Warren, Robin M ⁿ   Van Soolingen, Dick ^k,l   Murray, Megan ^b,t  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e ABT ASSOCIATES   (United States)

^f Boston University   (United States)

^g BOSTON UNIVERSITY   (United States)

^h Gen9 Inc   (United States)

ⁱ CSIRO   (Australia)

^j NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF MINHO   (Portugal)

^m BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF STELLENBOSCH   (South Africa)

^o UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^p CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^q RUTGERS UNIVERSITY   (United States)

^r INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^s UNIVERSITY OF ANTWERP   (Belgium)

^t HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Molecular diagnostics; Multidrug resistant tuberculosis; Sensitivity and specificity

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; DNA; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; KATG PROTEIN; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AHPC GENE; ALR GENE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; DDL GENE; DIAGNOSTIC VALUE; EMBA GENE; EMBB GENE; EMBC GENE; ETHA GENE; FABG1 GENE; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GID GENE; GYRA GENE; GYRB GENE; INHA GENE; INIA GENE; INIB GENE; INIC GENE; KASA GENE; KATG GENE; MYCOBACTERIUM TUBERCULOSIS; NDH GENE; NONHUMAN; OXYR GENE; PHENOTYPE; PHYLOGENY; PNCA GENE; PRIORITY JOURNAL; PROMOTER REGION; RPOB GENE; RPSL GENE; RRL GENE; RRS GENE; SENSITIVITY AND SPECIFICITY; THYA GENE; TLYA GENE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANCE; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENES, BACTERIAL; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84981186588     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201510-2091OC     Document Type: Article

References (49)

1. World Health Organization. Global tuberculosis report 2014 [accessed 2015 Sept]. Available from: http://www.who.int/tb/publications/global-report/en/.
2. Small PM, Pai M. Tuberculosis diagnosis: time for a game change. N Engl J Med 2010;363:1070-1071.
3. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response [accessed 2015 Sept]. Available from: http://www.who.int/tb/features-archive/m-xdrtb-facts/en/index.html.
4. Horne DJ, Pinto LM, Arentz M, Lin S-YG, Desmond E, Flores LL, Steingart KR, Minion J. Diagnostic accuracy and reproducibility ofWHO-endorsed phenotypic drug susceptibility testing methods for first-line and secondline antituberculosis drugs. J Clin Microbiol 2013;51:393-401.
5. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2014 [accessed 2015 Sept]. Available from: http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809-eng.pdf?ua=1&ua=1.
6. Boehme CC, Nabeta P, Hillemann D, NicolMP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl JMed 2010;363:1005-1015.
7. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010;48:1683-1689.
8. Hanrahan CF, Dorman SE, Erasmus L, Koornhof H, Coetzee G, Golub JE. The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort study. PLoS One 2012;7:e49898.
9. Miotto P, Cirillo DM, Migliori GB. Drug resistance in Mycobacterium tuberculosis: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness. Chest 2015;147:1135-1143.
10. Jin J, Shen Y, Fan X, Diao N, Wang F, Wang S, Weng X, Zhang W. Underestimation of the resistance of Mycobacterium tuberculosis to second-line drugs by the new GenoType MTBDRsl test. J Mol Diagn 2013;15:44-50.
11. Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, MansjöM, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, et al. Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study. J Clin Microbiol 2015;53:2961-2969.
12. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, Bradley P, Iqbal Z, Feuerriegel S, Niehaus KE, Wilson DJ, et al.; Modernizing Medical Microbiology (MMM) Informatics Group. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 2015;15:1193-1202.
13. Coll F, McNerney R, Preston MD, Guerra-Assunç?o JA, Warry A, Hill-Cawthorne G, Mallard K, Nair M, Miranda A, Alves A, et al. Rapid determination of anti-tuberculosis drug resistance from wholegenome sequences. Genome Med 2015;7:51.
14. Farhat M, Sultana R, Murray M. Large scale sequencing of genetic determinants of drug resistance in Mycobacterium tuberculosis: implications for diagnostic design [abstract]. Am J Respir Crit Care Med 2015;191:A2184.
15. Vincent V, Rigouts L, Nduwamahoro E, Holmes B, Cunningham J, Guillerm M, Nathanson C-M, Moussy F, De Jong B, Portaels F, et al. The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis 2012;16: 24-31.
16. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35:907-914.
17. van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequencedependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991;29:2578-2586.
18. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, Allix C, Aristimuño L, Arora J, Baumanis V, et al. Mycobacterium tuberculosis complex genetic diversity: mining the Fourth International Spoligotyping Database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 2006;6:23.
19. Weniger T, Krawczyk J, Supply P, Niemann S, Harmsen D. MIRU-VNTRplus: a web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. Nucleic Acids Res 2010;38:W326-331.
20. Hardenbol P, Bané r J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, Fakhrai-Rad H, Ronaghi M, Willis TD, Landegren U, et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003;21:673-678.
21. Langmead B. Aligning short sequencing reads with Bowtie. Curr Protoc Bioinformatics 2010;Chapter 11:Unit 11.7.
22. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009;25:2078-2079.
23. Lunter G, Goodson M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res 2011;21:936-939.
24. Rimmer A, Mathieson I, Lunter G, McVean G. Wellcome Trust Centre for Human Genetics - Platypus. Platypus: an integrated variant caller. 2012 [accessed 2013 Oct]. Available from: http://www.well.ox.ac.uk/platypus.
25. Felsenstein J. PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics 1989;5:164-166.
26. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997;94: 9869-9874.
27. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011;28:2731-2739.
28. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2014;69:331-342.
29. Meacci F, Orrù G, Iona E, Giannoni F, Piersimoni C, Pozzi G, Fattorini L, Oggioni MR. Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient. J Clin Microbiol 2005;43:3114-3120.
30. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 2012;67:819-831.
31. Ewout W. Steyerberg. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer-Verlag; 2009.
32. Strobl C, Boulesteix A-L, Kneib T, Augustin T, Zeileis A. Conditional variable importance for random forests. BMC Bioinformatics 2008;9: 307.
33. Díaz-Uriarte R, Alvarez de André s S. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006;7:3.
34. Chen SL, Hung C-S, Xu J, Reigstad CS,Magrini V, Sabo A, Blasiar D, Bieri T, Meyer RR, Ozersky P, et al. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci USA 2006;103:5977-5982.
35. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009;6:e2.
36. Feuerriegel S, Köser CU, Niemann S. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother 2014;69:1205-1210.
37. Coll F, McNerney R, Guerra-Assunç?o JA, Glynn JR, Perdig?o J, Viveiros M, Portugal I, Pain A, Martin N, Clark TG. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun 2014;5:4812.
38. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, et al. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol 2014;52:781-789.
39. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55:2032-2041.
40. World Health Organization (WHO). A roadmap for ensuring quality tuberculosis diagnostics services within national laboratory strategic plans. 2010 [accessed 2015 Sept]. Available from: http://www.who.int/tb/laboratory/gli-roadmap.pdf.
41. Huff LM, Lee J-S, Robey RW, Fojo T. Characterization of gene rearrangements leading to activation of MDR-1. J Biol Chem 2006; 281:36501-36509.
42. Sandegren L, Andersson DI. Bacterial gene amplification: implications for the evolution of antibiotic resistance. Nat Rev Microbiol 2009;7:578-588.
43. Zaunbrecher MA, Sikes RD Jr, Metchock B, Shinnick TM, Posey JE. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009;106:20004-20009.
44. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE III, Wang H, Zhang W, Zhang Y. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011;333:1630-1632.
45. Shi W, Chen J, Feng J, Cui P, Zhang S, Weng X, ZhangW, Zhang Y. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microbes Infect 2014;3: e58.
46. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2012; 44:106-110.
47. Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013;369:290-292.
48. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006;194:S51-S58.
49. Huang W-L, Chi T-L, Wu M-H, Jou R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2011;49:2502-2508.